Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18245008 | 0.80 | SLC22A1 (0.36) | SLC22A1MEN1KMT2AOPRM1SMN1; SMN2 | |
| SCHEMBL419719 | 0.75 | SLC22A1 (0.36) | SLC22A1MEN1KMT2AOPRM1SMN1; SMN2 | |
| SCHEMBL5655030 | 0.74 | SLC22A1 (0.35) | SLC22A1MEN1KMT2AOPRM1SMN1; SMN2 | |
| SCHEMBL6558544 | 0.74 | ATM (0.35) | SLC22A1MEN1KMT2AOPRM1SMN1; SMN2 | |
| SCHEMBL25061772 | 0.66 | TP53 (0.39) | MEN1KMT2AATMMAPK1 | |
| SCHEMBL18252879 | 0.66 | POLB (0.32) | ATM | |
| SCHEMBL18252889 | 0.66 | ATM (0.39) | SLC22A1MEN1KMT2AOPRM1SMN1; SMN2 | |
| SCHEMBL12868735 | 0.65 | ALDH1A1 (0.39) | SLC22A1MEN1KMT2AOPRM1SMN1; SMN2 | |
| SCHEMBL14838831 | 0.65 | SLC22A1 (0.40) | SLC22A1MEN1KMT2AOPRM1SMN1; SMN2 | |
| SCHEMBL26699471 | 0.65 | OPRM1 (0.35) | SLC22A1MEN1KMT2AOPRM1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054484-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-108135168-B | CCR2 modulators | 凯莫森特里克斯股份有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-3297438-A1 | CCR2 MODULATORS | ChemoCentryx, Inc. (US) | 2018-03-28 | — | — | EP | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| WO-2016187393-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | SLC22A1 1647/4885MEN1 4868/4885KMT2A 4009/4885 |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | SLC22A1 1647/4885MEN1 4868/4885KMT2A 4009/4885 |
| US-12054484-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | SLC22A1 1742/4885MEN1 4860/4885KMT2A 4485/4885 |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | SLC22A1 1647/4885MEN1 4868/4885KMT2A 4009/4885 |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | SLC22A1 1914/4885MEN1 4864/4885KMT2A 4477/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | SLC22A1 1662/4885MEN1 4866/4885KMT2A 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.